Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
about
Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma modelIdentification of novel tumor-associated cell surface sialoglycoproteins in human glioblastoma tumors using quantitative proteomicsTenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro.Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas.Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumorsCommon astrocytic programs during brain development, injury and cancerTenascins and the importance of adhesion modulation.Molecular targeted α-particle therapy for oncologic applications.Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localizationHeat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfacesLabeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligandsUse of antibodies and immunoconjugates for the therapy of more accessible cancers.Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanismsPharmacogenomics of brain cancer and personalized medicine in malignant gliomas.Trends in therapeutic monoclonal antibodies of cancer.Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability.The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.Microenvironment and tumor progression of melanoma: new therapeutic prospectives.Radioimmunotherapy for high-grade glioma.Molecular recognition force spectroscopy study of the dynamic interaction between aptamer GBI-10 and extracellular matrix protein tenascin-C on human glioblastoma cell.A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.Proteome and Secretome Characterization of Glioblastoma-Derived Neural Stem Cells.
P2860
Q28541327-42BE0180-B770-444D-9E6F-A6346B04E30DQ28544645-6A89CE18-3EE0-4BFB-8C38-249BDE5913C2Q33694568-4BF54E1F-A701-4F66-A0DC-2ECBB057F2C6Q34160678-AC7CB83C-E80A-46A8-904F-DA6BBFA3FF5EQ34286194-952F900A-F7C7-4BF9-9D43-ACB229B4FAD8Q34402770-4D4C3051-00D7-4BC3-9DDF-2CD860CBFC9BQ34549708-C1ACB1F1-4089-4744-8FE4-8E6437DFB936Q35006502-9D728413-08DC-49A5-878A-7FDACDC654A4Q35814989-B2683B51-3E9E-4B6F-8E4A-10DD2C792702Q36578825-DA4B0260-507D-41C4-812B-4C4DBCFCE970Q36922469-7CA81B88-2EA8-4FC2-91EC-0A0F66EAB001Q37145574-E36EA57C-848F-49C5-94EE-25A2331F36CBQ37174938-D281D613-9B83-46C8-986A-B1D8034B6370Q37208797-219ED981-A263-40A6-96BB-63889C1C2D82Q37236431-E71023C5-69DC-4B2C-9EF5-3C70A129D046Q37689796-026FBE30-E8D7-43A5-8156-8E02B6F682F7Q37724215-DB340077-0E2C-4074-9151-5E601558647EQ37964960-5824B611-CB91-4175-B360-47DBE06620E4Q38049368-ECC84991-6A1E-49E9-825D-C75952080AD2Q38110937-F67CA8EC-86F8-4937-B9E1-CA850916540AQ38318879-C3EF0581-2696-4AB6-B205-169FE519D480Q39284797-9060BFE1-C25C-4856-BC95-1B428E3CE233Q47400332-B2114A59-87B5-490F-A876-EF1AC1F4A5B0Q47965779-EB7EF914-B4F8-49E8-98D6-50E1FDFB17D3Q48422165-EC0569BB-D3D5-41AF-A875-516B1163A9A0
P2860
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
@ast
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
@en
type
label
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
@ast
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
@en
prefLabel
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
@ast
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
@en
P2860
P356
P1476
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
@en
P2093
Michael R Zalutsky
P2860
P304
P356
10.1586/14737140.7.5.675
P577
2007-05-01T00:00:00Z